Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $611.0.

  • China Pharma Holdings' Capital Expenditures rose 10662.69% to $611.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $78415.0, marking a year-over-year increase of 3459.26%. This contributed to the annual value of $38411.0 for FY2024, which is 23351.57% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Capital Expenditures is $611.0, which was up 10662.69% from -$65.0 recorded in Q2 2025.
  • China Pharma Holdings' Capital Expenditures' 5-year high stood at $415977.0 during Q3 2021, with a 5-year trough of -$55964.0 in Q1 2023.
  • Over the past 5 years, China Pharma Holdings' median Capital Expenditures value was $4527.0 (recorded in 2023), while the average stood at $60380.6.
  • In the last 5 years, China Pharma Holdings' Capital Expenditures tumbled by 412329.26% in 2023 and then soared by 33174.29% in 2024.
  • Quarter analysis of 5 years shows China Pharma Holdings' Capital Expenditures stood at $7056.0 in 2021, then plummeted by 486.45% to -$27268.0 in 2022, then surged by 116.6% to $4527.0 in 2023, then surged by 331.74% to $19545.0 in 2024, then crashed by 96.87% to $611.0 in 2025.
  • Its Capital Expenditures was $611.0 in Q3 2025, compared to -$65.0 in Q2 2025 and $58324.0 in Q1 2025.